跳至主要内容
临床试验/IRCT20181224042104N1
IRCT20181224042104N1招募中2 期

Determination of efficacy and safety of adding Oxaliplatin to neoadjuvant chemotherapy in locally advanced breast cancer patients

Shiraz University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 70 years(—)
性别
Female

入选标准

  • Histologically confirmed locally advanced breast cancer
  • Clinical stage T3, T4, and/or N2, N3
  • Patients with Eastern Cooperative Oncology Group performance status of 0 or 1
  • Absolute neutrophil count > 1500/ mm3
  • Hemoglobin > 8.0 g/dL
  • Platelet count > 100,000/mm3
  • Creatinine < 2.5 times the upper limit of normal (ULN)
  • Serum transaminases < 2.5 times ULN
  • Serum alkaline phosphatase < 4 times ULN
  • Total bilirubin < 2.5 times

排除标准

  • Active infection
  • Other primary malignancy
  • Any documented distant metastasis
  • Uncontrolled systemic diseases (including severe cardiovascular, kidney and liver disease)
  • Patients refusal to participate in the trial

研究者

相似试验